Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pediatr Endocrinol Metab ; 21(9): 895-903, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18924582

RESUMO

We describe 3 years follow-up of glyburide therapy in a child with permanent neonatal diabetes mellitus (PND) born to a 19 year-old mother with congenital diabetes mellitus. Genetic analysis identified a KCNJ11 mutation (R201H) in both the child and her mother. After 2 years of insulin therapy, the patient was switched to oral glyburide. After initial stabilization, glyburide therapy resulted in a marked decrease in glucose excursions in comparison to insulin. The patient had 3-10 episodes of hypoglycemia per week, including a total of eight episodes resulting in seizures, while on insulin. In contrast, no severe hypoglycemia was reported on glyburide. The patient's basal C-peptide was undetectable on insulin therapy (< 166 pmol/l) but was easily detectable on glyburide (189-761 pmol/l). The range of HbA1c improved significantly from 8-12% on insulin to 4.7-6% on glyburide. The frequency of glucose monitoring was gradually decreased from 4-8 times to 2-3 times a day on oral glyburide. This report confirms the superiority of sulfonylurea therapy in the treatment of PND with Kir6.2 mutations and shows sustained improved glycemic control over a 3-year follow-up period. Genetic exploration in other family members with diabetes might provide further insight into the nature of familial neonatal diabetes.


Assuntos
Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/genética , Glibureto/uso terapêutico , Hipoglicemiantes/uso terapêutico , Mutação/genética , Canais de Potássio Corretores do Fluxo de Internalização/genética , Glicemia/metabolismo , Pré-Escolar , Diabetes Mellitus/congênito , Feminino , Seguimentos , Hemoglobinas Glicadas/metabolismo , Humanos , Estudos Longitudinais , Resultado do Tratamento
2.
Cancer Treat Rev ; 34(8): 682-92, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18583061

RESUMO

Kisspeptin (KiSS-1) gene, initially described as a melanoma metastasis suppressor gene, encodes a number of peptides (kp-54, kp-14, kp-13, kp-10), which are endogenous ligands to a G protein-coupled receptor, referred as hOT7T175 or AXOR12 or GPR54. So far intensive investigation has provided substantiate evidence supporting the role of KiSS-1/GPR54 system in cancer biology as well as in the regulation of the reproductive function and trophoblast invasion. The precise mechanism by which KiSS-1/GPR54 system is affecting cancer cell growth and metastasis includes complex endocrine, paracrine and autocrine actions. Nevertheless, the detail mechanism of such actions is still under intensive investigation. Herein we review the evidence which support the role of KiSS-1/GPR54 system in cancer biology.


Assuntos
Predisposição Genética para Doença/epidemiologia , Neoplasias/genética , Polimorfismo Genético , Receptores Acoplados a Proteínas G/genética , Animais , Apoptose/genética , Feminino , Regulação Neoplásica da Expressão Gênica , Genes Neoplásicos , Humanos , Masculino , Mutação , Metástase Neoplásica/genética , Receptores de Kisspeptina-1 , Sensibilidade e Especificidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...